NCT04027803View on ClinicalTrials.gov

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

April 7, 2019

Study Completion Date

April 7, 2019

Conditions
Healthy Subjects
Interventions
BIOLOGICAL

BCD-148

single intravenous infusion of BCD-148 (900 mg)

BIOLOGICAL

Soliris

single intravenous infusion of Soliris (900 mg)

Trial Locations (1)

Unknown

Limited Liability Company Research Center Eco-Bezopasnost (OOO Research Center Eco-Bezopasnost), Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® | Biotech Hunter | Biotech Hunter